{"status": "Ok", "redirect_url": "https://www.investor.jnj.com/investor-news/news-details/2026/RYBREVANT-amivantamab-vmjw-plus-LAZCLUZE-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-EGFR-mutated-non-small-cell-lung-cancer/default.aspx", "message": "News view counter 767459 successfully enlarged"}